ResearcherCleveland ClinicNo recent work listed
Gareth J Morris‐Stiff
Matched on ORCID iD 0000-0002-1194-4133; OpenAlex author ID A5103184738. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 12
2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper
Papers 8
- Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis. First author DOI 10.1016/j.hbpd.2020.08.001↗
- Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer. Last author DOI 10.1016/j.hbpd.2019.05.007↗
- Next-Generation Sequencing in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001324↗
- Imaging mimics of pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00261-017-1330-1↗
- Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Costs. Co-author DOI 10.1007/s11605-017-3470-6↗
- Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. Co-author DOI 10.1002/cncr.29298↗
- Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Last author DOI 10.1016/s1499-3872(14)60284-8↗
- Ca19-9 and pancreatic cancer: Is it really that good? Co-author DOI 10.3978/j.issn.2078-6891.2012.016↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Richard Matthew Walsh · 5 shared papers, 2015–2021 · strength 0.52
- Paper Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A … DOI 10.1016/j.hbpd.2020.08.001↗
- Paper Next-Generation Sequencing in Pancreatic Cancer. DOI 10.1097/mpa.0000000000001324↗
- Paper Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer. DOI 10.1016/j.hbpd.2019.05.007↗
- Sricharan Chalikonda · 4 shared papers, 2015–2021 · strength 0.38
- Paper Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A … DOI 10.1016/j.hbpd.2020.08.001↗
- Paper Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer. DOI 10.1016/j.hbpd.2019.05.007↗
- Paper Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Cos… DOI 10.1007/s11605-017-3470-6↗
- June S. Peng · 3 shared papers, 2017–2021 · strength 0.33
- Paper Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A … DOI 10.1016/j.hbpd.2020.08.001↗
- Paper Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer. DOI 10.1016/j.hbpd.2019.05.007↗
- Paper Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Cos… DOI 10.1007/s11605-017-3470-6↗
- Gong-Qing Shen · 1 shared paper, 2019 · strength 0.14
- Ott Le · 1 shared paper, 2018 · strength 0.12
- Myra Feldman · 1 shared paper, 2018 · strength 0.12
- Namita Sharma Gandhi · 1 shared paper, 2018 · strength 0.12
- Daniela S. Allende · 1 shared paper, 2019 · strength 0.11
- Mark Taylor · 1 shared paper, 2012 · strength 0.06
- Jawad Elsayed Ahmad · 1 shared paper, 2014 · strength 0.06
- Davendra P. S. Sohal · 1 shared paper, 2015 · strength 0.05
- Alok A. Khorana · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.